Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $684.83 million. The enterprise value is $663.65 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 90.83 million shares outstanding. The number of shares has increased by 33.83% in one year.
| Current Share Class | 90.83M |
| Shares Outstanding | 90.83M |
| Shares Change (YoY) | +33.83% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 3.79% |
| Float | 20.46M |
Valuation Ratios
The trailing PE ratio is 444.13 and the forward PE ratio is 24.07.
| PE Ratio | 444.13 |
| Forward PE | 24.07 |
| PS Ratio | 6.56 |
| Forward PS | 9.94 |
| PB Ratio | 7.64 |
| P/TBV Ratio | 8.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 773.06 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 159.34 |
| EV / Sales | 6.49 |
| EV / EBITDA | 57.90 |
| EV / EBIT | 71.05 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.40, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.40 |
| Quick Ratio | 4.68 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.84% and return on invested capital (ROIC) is 5.16%.
| Return on Equity (ROE) | 7.84% |
| Return on Assets (ROA) | 4.27% |
| Return on Invested Capital (ROIC) | 5.16% |
| Return on Capital Employed (ROCE) | 6.88% |
| Revenue Per Employee | $176,492 |
| Profits Per Employee | $7,193 |
| Employee Count | 579 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 0.58 |
Taxes
In the past 12 months, GYRE has paid $2.84 million in taxes.
| Income Tax | 2.84M |
| Effective Tax Rate | 24.54% |
Stock Price Statistics
The stock price has decreased by -45.11% in the last 52 weeks. The beta is 7.11, so GYRE's price volatility has been higher than the market average.
| Beta (5Y) | 7.11 |
| 52-Week Price Change | -45.11% |
| 50-Day Moving Average | 7.81 |
| 200-Day Moving Average | 8.90 |
| Relative Strength Index (RSI) | 49.65 |
| Average Volume (20 Days) | 86,479 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GYRE had revenue of $102.19 million and earned $4.17 million in profits. Earnings per share was $0.02.
| Revenue | 102.19M |
| Gross Profit | 98.01M |
| Operating Income | 9.34M |
| Pretax Income | 11.58M |
| Net Income | 4.17M |
| EBITDA | 11.46M |
| EBIT | 9.34M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $54.37 million in cash and $1.39 million in debt, giving a net cash position of $52.97 million or $0.58 per share.
| Cash & Cash Equivalents | 54.37M |
| Total Debt | 1.39M |
| Net Cash | 52.97M |
| Net Cash Per Share | $0.58 |
| Equity (Book Value) | 129.44M |
| Book Value Per Share | 1.01 |
| Working Capital | 74.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $927,000 and capital expenditures -$1.01 million, giving a free cash flow of -$79,000.
| Operating Cash Flow | 927,000 |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -79,000 |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
Gross margin is 95.91%, with operating and profit margins of 9.14% and 4.08%.
| Gross Margin | 95.91% |
| Operating Margin | 9.14% |
| Pretax Margin | 11.33% |
| Profit Margin | 4.08% |
| EBITDA Margin | 11.22% |
| EBIT Margin | 9.14% |
| FCF Margin | n/a |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.83% |
| Shareholder Yield | -33.83% |
| Earnings Yield | 0.58% |
| FCF Yield | -0.01% |
Dividend DetailsAnalyst Forecast
The average price target for GYRE is $17.00, which is 125.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 125.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 26.98 and a Piotroski F-Score of 4.
| Altman Z-Score | 26.98 |
| Piotroski F-Score | 4 |
